Targeted bcg vaccination against severe tuberculosis in low-prevalence settings epidemiologic and economic assessment

Epidemiology

Volumn 20, Issue 4, 2009, Pages 562-568

  Altes, Hester Korthals ^a   Dijkstra, Frederika ^a   Lugnèr, Anna ^a   Cobelens, Frank ^b,c   Wallinga, Jacco ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; CHILD; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IMMIGRANT; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STATISTICAL MODEL; TUBERCULOSIS; TUBERCULOSIS CONTROL;

BCG VACCINE; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; NETHERLANDS; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS;

EID: 67651071055     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e31819e3c1a     Document Type: Article

References (30)

1. Milstien JB. Immunological Basis for Immunization. Module 5: Tuberculosis. Geneva: World Health Organization; 1993.
2. Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. Issues Relating to the use of BCG in Immunization Programmes: A Discussion Document. Geneva: World Health Organization; 1999:42.
3. Powell DA, Hunt WG. Tuherculosis in children: an update. Adv Pediatr. 2006;53:279-322.
4. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuherculosis. Lancet. 2003;362:887-899.
5. World Health Organization.BCG vaccine. WHO position paper. Wkly Epidemiol Rec. 2004;79:27-38.
6. Infuso A, Falzon D. European survey of BCG vaccination policies and surveillance in children, 2005. Euro Surveill. 2006;11:6-11.
7. Watson JM. Tuherculosis and BCG in Europe. Euro Surveill. 2006;11:3-4.
8. Romanus V. Selective BCG vaccination in a country with low incidence of tuherculosis. Euro Surveill. 2006;11:14-7.
9. Hersh AL, Tala-Heikkila M, Tala E, Tosteson AN, Fordham von Reyn C. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis hacille Calmette-Guerin in Finland. Int J Tuberc Lung Dis. 2003;7:22-29.
10. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuherculous meningitis and miliary tuherculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173-1180.
11. Grassly NC, Fraser C, Wenger J, et al. New strategies for the elimination of polio from India. Science. 2006;314:1150-1153.
12. Centraal Bureau voor de Statistiek (CBS). Allochtonen per regio; herkomst; 2005.
13. Ruhin DB, Schenker N. Multiple imputation in health-care datahases: an overview and some applications. Stat Med. 1991;10:585-598.
14. Talhot EA, Perkins MD, Silva SF, Frothingham R. Disseminated hacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis. 1997;24:1139-1146.
15. Bernatowska EA, Wolska-Kusnierz B, Pac M, et al. Disseminated hacillus Calmette-Guerin infection and immunodeficiency. Emerg Infect Dis. 2007;13:799-801.
16. Welte R, van den Dohhelsteen G, Bos JM, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine. 2004;23:470.479.
17. Centraal Bureau voor de Statistiek (CBS). Overlevingstafels; 2005.
18. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21:402-408.
19. Melse JM, Essink-Bot ML, Kramers PG, Hoeymans N. A national hurden of disease calculation: Dutch disahility-adjusted life-years. Dutch Burden of Disease Group. Am J Public Health. 2000;90:1241-1247.
20. Baker SK, Glassroth J. Miliary tuherculosis. In: Rom WN, Garay SM, eds. Tuberculosis. Boston: Little Brown and Company; 1996:493-511.
21. Zuger A, Lowy FD. Tuherculosis of the hrain, meninges and spinal cord. In: Rom WN, Garay SM, eds. Tuberculosis. Boston: Little Brown and Company; 1996:541-556.
22. van den Bos F, Terken M, Ypma L, et al. Tuherculous meningitis and miliary tuherculosis in young children. Trop Med Int Health. 2004;9: 309-313.
23. Murray CJL, Lopez AD, eds. Global Burden ofDisease: A Comprehensive Assessment ofMortalityandDisabilityFrom Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Camhridge, MA: Harvard University Press; 1996.
24. College voor zorgverzekeringen (CVZ). Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie; 2006.
25. Casparie AF, van Hout BA, Simoons ML. Guidelines and costs [in Dutch]. Ned Tijdschr Geneeskd. 1998;142:2075-2077.
26. Bonifachich E, Chort M, Astigarraga A, et al. Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuherculosis, hut not the pulmonary disease. A case-control study in Rosario, Argentina. Vaccine. 2006;24:2894-2899.
27. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuherculosis. Meta-analysis of the puhlished literature. JAMA. 1994;271:698-702.
28. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuherculous meningitis and miliary tuherculosis: a meta-analysis. Int J Epidemiol. 1993;22:1154-1158.
29. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis. 1998;2:200-207.
30. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA. 2004;291:2086-2091.